Trusted Resources: Education
Scientific literature and patient education texts
Mucopolysaccharidosis Type VI (Maroteaux-Lamy Syndrome): Defining and Measuring Functional Impacts in Pediatric Patients
source: Orphanet journal of rare diseases
year: 2021
authors: Leiro B,Phillips D,Duiker M,Harmatz P,Charles S
summary/abstract:Research about pediatric patients’ perspective on mucopolysaccharidosis type VI (MPS VI) and its impact on daily life is limited. We aimed to identify the disease concepts of interest that most impact function and day-to-day life of pediatric patients with MPS VI, and to consider clinical outcome assessments (COAs) that may potentially measure meaningful improvements in these concepts.
organization: Phillips Consulting, Chapel Hill, NC, USA. [email protected].DOI: 10.1186/s13023-021-02113-8
read more
BookmarkRelated Content
-
Disease Burden, Management Patterns and Multidisciplinary Clinical Approaches for Patients With MPS IVA and VI in Se...There is a paucity of real-world epidemi...
-
Maroteaux Lamy SyndromeMaroteaux-Lamy syndrome (mucopolysacchar...
-
Deep Intronic Variant in the ARSB Gene as the Genetic Cause for Maroteaux-Lamy Syndrome (MPS VI)Maroteaux-Lamy syndrome (MPS-VI) is a ra...
-
A Guide to Understanding MPS VIMPS VI (Maroteaux-Lamy syndrome) is caus...
-
Oral Treatment for Mucopolysaccharidosis VI: Outcomes of the First Phase Iia Study With OdiparcilMucopolysaccharidosis (MPS) disorders ar...
-
Paul Harmatz, MDDr. Paul Harmatz is a Professor in Resid...
-
MPS VI (Maroteaux-Lamy Syndrome)https://www.onempsvoice.com/wp-content/u...
Powered by
